---
title: "JAZZ.US (JAZZ.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/JAZZ.US/news.md"
symbol: "JAZZ.US"
name: "JAZZ.US"
parent: "https://longbridge.com/en/quote/JAZZ.US.md"
datetime: "2026-05-21T05:57:19.161Z"
locales:
  - [en](https://longbridge.com/en/quote/JAZZ.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/JAZZ.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/JAZZ.US/news.md)
---

# JAZZ.US (JAZZ.US) — Related News

### [43,200 Shares in Jazz Pharmaceuticals PLC $JAZZ Bought by Tredje AP fonden](https://longbridge.com/en/news/287051994.md)
*2026-05-20T10:57:57.000Z*
> Tredje AP fonden acquired 43,200 shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) valued at approximately $7.34 million 

### [UBS upgrades Jazz Pharma rating: Core business shows strong resilience, new drug Ziihera becomes growth engine](https://longbridge.com/en/news/286920691.md)
*2026-05-19T13:20:30.000Z*
> UBS Group raised Jazz Pharma's rating to "Buy," with a target price increased to $307, indicating an upside potential of

### [Alkermes’ Lumryz, from $2.4B Avadel buy, hits phase 3 mark in IH](https://longbridge.com/en/news/286137280.md)
*2026-05-12T17:25:19.000Z*
> Alkermes has achieved a significant milestone with its $2.37 billion acquisition of Avadel, as the phase 3 study of Lumr

### [Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences | JAZZ Stock News](https://longbridge.com/en/news/286151263.md)
*2026-05-12T12:15:00.000Z*
> Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced its participation in upcoming investor conferences, including the RBC 

### [Werewolf Reports Q1 Loss Of $13 Mln, Highlights Asset Purchase Agreement With Jazz](https://longbridge.com/en/news/285710502.md)
*2026-05-08T10:55:34.000Z*
> Werewolf Therapeutics Inc. reported a Q1 2026 net loss of $13.53 million, improving from a loss of $18.09 million in Q1 

### [Jazz Pharmaceuticals (JAZZ) Q1 EPS Rebound Tests Bearish Margin Narratives](https://longbridge.com/en/news/285471810.md)
*2026-05-07T02:13:58.000Z*
> Jazz Pharmaceuticals (JAZZ) reported Q1 2026 revenue of $1.1 billion and basic EPS of $4.74, rebounding from a challengi

### [Jazz Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript](https://longbridge.com/en/news/285274687.md)
*2026-05-05T21:52:37.000Z*
> Jazz Pharmaceuticals reported record Q1 2026 revenue of $1.07 billion, driven by a 45% growth in its oncology portfolio.